Evidence map›Paper›PMID 26695440›Full record

ArticleOncotarget2016

Yap1 promotes the survival and self-renewal of breast tumor initiating cells via inhibiting Smad3 signaling.

Jian-Guo Sun, Xie-Wan Chen, Lu-Ping Zhang, Jiang Wang, Max Diehn

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Hippo/YAP signaling's multifaceted crosstalk in cancer.Frontiers in cell and developmental biology · 2025
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Jian-Guo SunCancer Institute, Stanford University School of Medicine, Stanford, California, USA.
Xie-Wan ChenDepartment of Oncology, Second Affiliated Hospital of Third Military Medical University, Chongqing, P.R. China.
Lu-Ping ZhangDepartment of Oncology, Second Affiliated Hospital of Third Military Medical University, Chongqing, P.R. China.
Jiang WangDepartment of Oncology, Second Affiliated Hospital of Third Military Medical University, Chongqing, P.R. China.
Max DiehnCancer Institute, Stanford University School of Medicine, Stanford, California, USA.
Army Medical University · CNStanford University · US

Funding

Cancer Stem Cells and Radiotherapy: New Approaches to RadiosensitizationP30CA147933 · NCI · STANFORD UNIVERSITY · PI MITCHELL, BEVERLY S. · 2009 to 2010
$1.6M
NCI NIH HHS P30 CA147933NCI NIH HHS P30CA147933
6 · The paper itself

Abstract

Tumor initiating cells (TICs) serve as the root of tumor growth. After identifying TICs in spontaneous breast tumors of the MMTV-Wnt1 mouse model, we confirmed the specific expression and activation of Yes-associated protein 1 (Yap1) within TICs. To investigate the role of Yap1 in the self-renewal of breast TICs and the underlying mechanism, we sorted CD49fhighEpCAMlow cells as breast TICs. Active Yap1 with ectopic expression in breast TICs promoted their colony formation in vitro (p< 0.01) and self-renewal in vivo (p< 0.01), and led to a 4-fold increase in TIC frequency (p< 0.05).A conditional knock-out mouse was reconstructed to generate Yap1 knock-out breast tumors. The loss of Yap1 led to a dramatic growth disadvantage of breast TICs in vitro (p< 0.01) and in vivo (p< 0.01), and it also led to an over 200-fold decrease in TIC frequency (p< 0.01). The expression of active Yap1 was negatively correlated with that of phosphorylated Smad3 (p-Smad3).Transforming growth factor β (TGF-β) served as a strong enhancer of Smad3 and an inhibitor of clonogenesis of TICs. The presence of SIS3, a specific inhibitor of Smad3, could rescue the TGF-β -induced growth inhibition and reverse the Smad3 inhibition by Yap1. Analysis of a database containing 2,072 human breast cancer samples showed that higher expressions of Yap1 correlated with a poorer outcome of a 15-year survival rate and median overall survival (mOS)in patients, especially in those with basal breast tumors without estrogen receptor 1 (ER) expression. The findings indicate that active Yap1 promotes the self-renewal of breast TICs by inhibiting Smad3 signaling.

Indexed as

Adaptor Proteins, Signal TransducingAnimalsBreast NeoplasmsCell Cycle ProteinsEstrogen Receptor alphaFemaleHumansIsoquinolinesMammary Neoplasms, ExperimentalMammary Tumor Virus, MouseMiceMice, KnockoutNeoplastic Stem CellsPhosphoproteinsPhosphorylationPyridines6,7-dimethyl-2-(2E)-3-(1-methyl-2-phenyl-1H-pyrrolo(2,3-b)pyridin-3-yl-prop-2-enoyl)-1,2,3,4-tetrahydroisoquinoline hydrochlorideAdaptor Proteins, Signal TransducingCell Cycle ProteinsESR1 protein, humanEstrogen Receptor alphaIsoquinolinesPhosphoproteinsPyridinesPyrrolesSmad3 ProteinSmad3 protein, mouseTranscription FactorsTransforming Growth Factor betaWnt1 ProteinWnt1 protein, mouseYAP1 protein, humanYap1 protein, mouseYAP-Signaling Proteinsbreast cancerself-renewalSmad3tumor initialing cellsYap1

Identifiers

PMID26695440
PMCPMC4891077
OpenAlexW2289342728

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.